Liquid chromatographic tandem mass spectrometric validated method for pharmacokinetic estimation of flecainide in human plasma

References

• Prescribing Information, on Tambacor, June 1998, 3M Pharmaceuticals, Northridge, CA 91324.
   Google Scholar
• Henthorn W, AL Waldo AL, Anderson JL, Gilbert EM, Alpert BL, Bhandari AK, Hawkinson RW, Pritchett EL. Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group Division of Cardiology, Christ Hospital, Cincinnati, Ohio 45219, Circulation, 83:119–125.
   Google Scholar
• Ramos E, O’ Leary ME. State-dependent trapping of flecainide in the cardiac sodium channel Department of Pathology, Anatomy and Cell Biology, Jefferson Medical College, 1020 Locust Street, Philadelphia, PA 19107, USA.
   Google Scholar
• Anderson J, Gilbert E, Alpert B, Henthorn R, Waldo A, Bhandari A, Hawkinson R, Pritchett E. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring, Flecainide Supraventricular Tachycardia Study Group. Circulation. 1989;80:557–570.
   Google Scholar
• Deneer VHM, Lie-A-Huen L, Kingma J H, Proost JH, Gossen SA, Stuurman A, Uytde Haag GMM, Dunselman PHJM, Brouwers JRBJ. Absorption kinetics and pharmacodynamics of two oral dosage forms of flecainide in patients with an episode of paroxysmal atrial fibrillation. Eur J Clin Pharmacol. 2004;60:693–701.
   PubMed Web of Science ®Google Scholar
• Straka R, Marshall P. The clinical significance of the pharmacogenetics of cardiovascular medications. Journal of Pharmacy Practice. 1992;5:337–361.
   Google Scholar
• Parfitt K (ed). Martindale—The complete drug reference, 32nd ed., Pharmaceutical Press, London, U.K., 1999;868–869.
   Google Scholar
• Doki K, Homma M, Kuga K, Kusano K, Watanabe S, Yamaguchi I, Kohda Y. Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia. Eur J Clin Pharmacol. 2006;62:919–926.
   PubMed Web of Science ®Google Scholar
• Breindahl T. Therapeutic drug monitoring of flecainide in serum using high-performance liquid chromatography and electrospray mass spectrometry. J Chromatogr B 2000;746:249–254.
   PubMedGoogle Scholar
• Wilson KM, Schneider JJ, Ravenscroft PJ. Improved solid phase extraction technique for plasma flecainide analysis by high performance liquid chromatography. Ther Drug Monit. 1998;20:435–438.
   PubMed Web of Science ®Google Scholar
• Guidance for Industry: Bioavailability and bioequivalence studies for orally administered drug products—General Considerations, 2003. Accessed February 22, 2007 at www. fda. gov/cder/guidance/5356fnl
   Google Scholar
• Method validation for extemporaneous pediatric formulation prototypes of Quinapril Hydrochloride/assay and stability method, Pfizer Global Research and Development, Ann Arbor, Michigan, November, 2001.
   Google Scholar
• Validation of analytical procedures: Methodology, ICH-Q2B, International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use, Geneva, Switzerland, 1996.
   Google Scholar
• U.S. Food and Drug Administration. Guidance for industry: Analytical procedures and method validation, Center for Drug Evaluation and Research, Rockville, Maryland, 2000.
   Google Scholar
• Validation of analytical Methods for drug products, Pfizer Global Research and Development, Ann Arbor, Michigan, 2001.
   Google Scholar
• Carlson, RV, Boyd KM. The revision of the Declaration of Helsinki: Past, present and future. Br J Clin Pharmacol. 2004;57:695–713.
   PubMed Web of Science ®Google Scholar
• Guidance for Institutional Review Boards and Clinical Investigators 1998 Update Information Sheets: 21 CFR Part 56—Institutional Review Boards INFORMATION SHEETS Guidance for Institutional Review Boards and Clinical Investigators 1998 Update Appendix C 21 CFR Part 56— Institutional Review Boards.
   Google Scholar
• Food and Drug Administration. Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products—General considerations (March 2003). Accessed February 22, 2007 at www.fda.gov/cder/guidance/5356fnl.pdf.
   Google Scholar
• Schuirmann DJ. A comparison of two one-sided test procedure and the power approach for assessing the equivalence of the average bioavailability. J Pharmacokinet Biopharm. 1987;15:657–680.
   PubMedGoogle Scholar
• Chow CS, Liu JP. Design and analysis of bioavailability and bioequivalence studies, Marcel Dekker: New York, 1992.
   Google Scholar
• Doki K, M. Homma M, Kuga K, Watanabe S, Yamaguchi I, Kohda Y. Simultaneous determination of serum flecainide and its metabolites by using high performance liquid chromatography. J Pharm Biomed Anal. 2004;35(5):1307–1312.
   PubMed Web of Science ®Google Scholar
• Nakagawa R, Homma M, Kuga K, Yamaguchi I, D. Kobayashi D, Morimoto Y, Kohda Y. High performance liquid chromatography for routine monitoring of serum flecainide. J Pharm Biomed Anal. 2002;30(1):171–174.
   PubMed Web of Science ®Google Scholar
• Tennezé L, Tarral E, Ducloux N, Funck-Brentano C. Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: comparison with the standard form and influence of the CYP2D6 polymorphism, Clin Pharmacol Ther. 2002;72(2):112–122.
   PubMed Web of Science ®Google Scholar
• Lie-A-Huen L, Proost JH, Kingma JH, Meijer DK., Absorption kinetics of oral and rectal flecainide in healthy subjects, Eur J Clin Pharmacol. 1990;38(6):595–598.
   PubMed Web of Science ®Google Scholar
• Doki K, Homma M, Kuga K, Aonuma K, Sakai S, Yamaguchi I, Kohda Y. Gender-associated differences in pharmacokinetics and anti-arrhythmic effects of flecainide in Japanese patients with supraventricular tachyarrhythmia. Eur J Clin Pharmacol, 2007;63(10): 951–957.
   PubMed Web of Science ®Google Scholar
• Sayalero ML, Lanao JM, Barrueco M, Dominguez-Gil A. Eur J Drug Metab Pharmacokinet. 1991;3:216–220.
   Web of Science ®Google Scholar
• Barett JS, Batra V, Chow A, Cook J, Gould AL, Heller AH, Lo MW, Pattersn SD, Smith BP, Stritar JA, Vega JM, Zariffa N. PhRMA perspective on population and individual bioequivalence. J Clin Pharmacol. 2000;40:561.
   PubMed Web of Science ®Google Scholar